Table 1.

Characteristics of 902 men with prostate cancer in the PHS and HPFS according to PSMA expression in tumor tissue

PSMA quartile (Q)
All patientsQ1 (low)Q2Q3Q4 (high)P
N cases902225226226225
Mean (SD) age at diagnosis, y65.8 (6.3)65.1 (6.4)66.2 (6.3)65.2 (6.7)66.8 (5.6)<0.01a
Mean (SD) follow-up time, y13.2 (5.0)13.6 (5.1)13.1 (4.9)13.4 (5.0)12.6 (4.8)0.13a
Tumor stage, N (%)
 T1–T2, N0–Nx, M0–Mx640 (71.0)173 (76.9)166 (73.5)144 (63.7)157 (69.8)0.07b
 T3, N0–Nx, M0–Mx222 (24.6)45 (20.0)49 (21.7)70 (31.0)58 (25.8)
 T4 or N1 or M138 (4.2)6 (2.7)11 (4.9)12 (5.3)9 (4.0)
 Missing2 (0.2)1 (0.4)001 (0.4)
Gleason score, N (%)
 2–6178 (19.7)70 (31.1)57 (25.2)36 (15.9)15 (6.7)<0.01c
 3 + 4335 (37.1)100 (44.4)84 (37.2)82 (36.3)69 (30.7)
 4 + 3223 (24.7)29 (12.9)52 (23.0)64 (28.3)73 (34.7)
 8–10166 (18.4)26 (11.6)33 (14.6)44 (19.5)63 (28.0)
PSA at diagnosis, ng/mL
 Median (IQR)7.0 (5.0,11.0)7.0 (4.8,9.9)6.5 (4.7,9.3)7.5 (5.0,12.5)7.6 (5.5,13.0)<0.01d
 Categories, N (%)
  <487 (9.7)26 (11.6)28 (12.4)21 (9.3)12 (5.3)0.01b
  4 to <10449 (49.8)118 (52.4)120 (53.1)109 (48.2)102 (45.3)
  ≥10231 (25.6)47 (20.9)48 (21.2)65 (28.8)71 (31.6)
  Missing135 (15.0)34 (15.1)30 (13.3)31 (13.7)40 (17.8)
BMI at diagnosis, kg/m2
 Mean (SD)25.6 (3.4)25.6 (3.3)25.7 (4.2)25.5 (3.0)25.6 (3.1)0.91a
Categories, N (%)
  < 25379 (42.0)96 (42.7)104 (46.0)86 (38.1)93 (41.3)0.40b
  25 to <28276 (30.6)73 (32.4)64 (28.3)81 (35.8)58 (25.8)
  ≥28155 (17.2)39 (17.3)39 (17.3)35 (15.5)42 (18.7)
  Missing92 (10.2)17 (7.6)19 (8.4)24 (10.6)32 (14.2)
  • aANOVA test; 3 degrees of freedom. Excluded individuals with missing values.

  • bChi-square test; 6 degrees of freedom. Excluded individuals with missing values.

  • cChi-square test; 9 degrees of freedom.

  • dKruskal–Wallis test; 3 degrees of freedom. Excluded individuals with missing values.